Larimar Therapeutics
Azriel Schmidt has been working in the scientific field since 1981. Azriel began their career as a Visiting Associate at the National Institutes of Health in 1981. In 1985, they moved to Rorer Pharmaceutical as a Section Manager. In 1989, they joined Merck & Co as a Distinguished Senior Investigator. In 2016, they became a Scientific Consultant at Chondrial Therapeutics LLC. In 2010, they began working as a Scientific Consultant at HaRo Pharmaceutical Inc. and in 2020 they joined Larimar Therapeutics Inc. in the same role.
Azriel Schmidt began their educational journey at Tel Aviv University, where they earned a B.Sc. in Biology from 1969 to 1972. Azriel then continued their studies at Tel Aviv University, earning an M.Sc. in Microbiology from 1973 to 1975. In 1976, they moved to the Weizmann Institute of Science, where they earned a Ph.D. in Biology (virology) in 1980. In 2014, they completed the I-Corps@NIH Program.
This person is not in any offices
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.